600 Shares in Glaukos Co. (NYSE:GKOS) Bought by Asset Planning Inc

Asset Planning Inc purchased a new stake in shares of Glaukos Co. (NYSE:GKOS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 600 shares of the medical instruments supplier’s stock, valued at approximately $90,000.

Other hedge funds also recently bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in shares of Glaukos in the third quarter valued at $25,000. Harvest Fund Management Co. Ltd raised its stake in shares of Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares during the period. KBC Group NV raised its stake in shares of Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares during the period. EWA LLC purchased a new stake in shares of Glaukos in the third quarter valued at $209,000. Finally, Procyon Advisors LLC purchased a new stake in shares of Glaukos in the third quarter valued at $210,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GKOS. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and increased their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. Wells Fargo & Company raised their price target on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Truist Financial raised their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus raised their price target on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $151.08.

Insider Activity

In other news, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at $4,859,454.08. This represents a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,328 shares of company stock worth $2,289,521. Corporate insiders own 6.40% of the company’s stock.

Glaukos Stock Up 1.8 %

NYSE:GKOS opened at $146.29 on Friday. Glaukos Co. has a fifty-two week low of $83.90 and a fifty-two week high of $163.71. The stock has a market capitalization of $8.07 billion, a P/E ratio of -48.44 and a beta of 1.04. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company’s 50-day simple moving average is $151.20 and its 200-day simple moving average is $137.79.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.